全球制药业迎来重大合作，诺华制药和礼来公司日前宣布，他们已与Alphabet旗下的创新人工智能制药企业Isomorphic Labs达成战略合作协议，总价值高达30亿美元。这一开创性的合作标志着科技巨头谷歌在医药研发领域的进一步深入。
Isomorphic Labs在官方发布中表示，此次与诺华和礼来的合作将聚焦于多靶点的小分子药物研发，旨在利用先进的AI技术加速药物发现和创新进程。合作的财务条款包括近30亿美元的初始价值，未来还有可能因药物销售产生的特许权使用费，进一步提升合作的潜在回报。
诺华和礼来，作为全球制药行业的领军企业，此次联手Isomorphic Labs，旨在利用AI的预测和分析能力，提升药物研发的效率和成功率。通过AI技术，企业有望在早期阶段识别出更有效的治疗方案，从而为患者带来更及时的医疗解决方案。
这一合作预示着人工智能在医药行业的应用将进入一个全新的阶段，不仅可能重塑药物研发的模式，还可能为全球医疗健康领域带来革命性的变革。随着科技与医药的深度融合，我们有望见证更多创新疗法的诞生，以应对各种复杂疾病的挑战。
英语如下：
**News Title:** “Novartis, Lilly, and Alphabet’s Isomorphic Labs Join Forces for a $3 Billion AI-Powered Pharmaceutical Revolution”
**Keywords:** AI制药, 诺华礼来, 30亿合作
**News Content:**
In a major collaboration in the global pharmaceutical industry, Novartis and Eli Lilly have recently announced a strategic partnership with Isomorphic Labs, an innovative AI-driven pharmaceutical company under Alphabet, with a total value of $3 billion. This groundbreaking alliance signifies Google’s further foray into drug research and development.
Isomorphic Labs stated in an official release that the collaboration with Novartis and Lilly will focus on the development of multi-target small molecules, leveraging advanced AI technologies to expedite drug discovery and innovation. The financial terms of the partnership involve an initial value of nearly $3 billion, with the potential for additional royalty payments from drug sales, thereby enhancing the potential returns.
As leaders in the global pharmaceutical sector, Novartis and Lilly’s collaboration with Isomorphic Labs aims to harness AI’s predictive and analytical capabilities to increase the efficiency and success rate of drug development. By leveraging AI technology, the companies aspire to identify more effective treatment options at earlier stages, thus providing patients with more timely therapeutic solutions.
This partnership signals a new era for the application of artificial intelligence in the pharmaceutical industry, potentially reshaping drug development models and bringing about revolutionary changes to global healthcare. As technology and医药 converge, we can anticipate the emergence of more innovative therapies to address the challenges posed by various complex diseases.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 1